Trial Profile
Randomized, double-blind, parallel-group, placebo-controlled,ezetimibe-calibrated, multicenter study evaluating the safety and efficacy of 4 doses and 2 dose-regimens of AVE5530 (4 wks) in patients with mild to moderate hypercholesterolemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Canosimibe (Primary) ; Ezetimibe (Primary)
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- Sponsors Sanofi
- 15 Dec 2008 Ezetimibe identified as an additional treatment arm as reported by ClinicalTrials.gov.
- 15 Dec 2008 Actual patient number (206) added as reported by ClinicalTrials.gov.
- 15 Dec 2008 Actual end date (Oct 2007) added as reported by ClinicalTrials.gov.